CN106883272B - 双黄酮-铁配合物及其制备方法和应用 - Google Patents
双黄酮-铁配合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN106883272B CN106883272B CN201710097598.4A CN201710097598A CN106883272B CN 106883272 B CN106883272 B CN 106883272B CN 201710097598 A CN201710097598 A CN 201710097598A CN 106883272 B CN106883272 B CN 106883272B
- Authority
- CN
- China
- Prior art keywords
- biflavone
- ame
- complex
- iron complex
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title abstract description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 61
- 238000000034 method Methods 0.000 claims abstract description 13
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 7
- 229910052742 iron Inorganic materials 0.000 claims abstract description 7
- 150000002500 ions Chemical class 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 72
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 238000006243 chemical reaction Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000001376 precipitating effect Effects 0.000 claims description 12
- 238000005406 washing Methods 0.000 claims description 10
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 claims description 8
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 5
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 5
- 229910002651 NO3 Inorganic materials 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- VCJMYUPGQJHHFU-UHFFFAOYSA-N iron(3+);trinitrate Chemical compound [Fe+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O VCJMYUPGQJHHFU-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- HITDPRAEYNISJU-UHFFFAOYSA-N amenthoflavone Natural products Oc1ccc(cc1)C2=COc3c(C2=O)c(O)cc(O)c3c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HITDPRAEYNISJU-UHFFFAOYSA-N 0.000 abstract description 17
- YUSWMAULDXZHPY-UHFFFAOYSA-N amentoflavone Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 YUSWMAULDXZHPY-UHFFFAOYSA-N 0.000 abstract description 17
- HVSKSWBOHPRSBD-UHFFFAOYSA-N amentoflavone Natural products Oc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O HVSKSWBOHPRSBD-UHFFFAOYSA-N 0.000 abstract description 17
- NQJGJBLOXXIGHL-UHFFFAOYSA-N podocarpusflavone A Natural products COc1ccc(cc1)C2=CC(=O)c3c(O)cc(O)c(c3O2)c4cc(ccc4O)C5=COc6cc(O)cc(O)c6C5=O NQJGJBLOXXIGHL-UHFFFAOYSA-N 0.000 abstract description 17
- 230000000259 anti-tumor effect Effects 0.000 abstract description 15
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 abstract description 15
- 238000003556 assay Methods 0.000 abstract description 7
- 238000000862 absorption spectrum Methods 0.000 abstract description 6
- -1 iron ion Chemical class 0.000 abstract description 6
- 238000007540 photo-reduction reaction Methods 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 3
- 238000004566 IR spectroscopy Methods 0.000 abstract description 2
- 238000001819 mass spectrum Methods 0.000 abstract description 2
- 239000003446 ligand Substances 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000000243 solution Substances 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 20
- 235000019441 ethanol Nutrition 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 9
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 238000005303 weighing Methods 0.000 description 8
- 238000001953 recrystallisation Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 5
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 229960001285 quercetin Drugs 0.000 description 5
- 235000005875 quercetin Nutrition 0.000 description 5
- 150000005837 radical ions Chemical class 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- MVFCKEFYUDZOCX-UHFFFAOYSA-N iron(2+);dinitrate Chemical compound [Fe+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MVFCKEFYUDZOCX-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 125000000490 cinnamyl group Chemical group C(C=CC1=CC=CC=C1)* 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 229910052761 rare earth metal Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229910016874 Fe(NO3) Inorganic materials 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- NQXWGWZJXJUMQB-UHFFFAOYSA-K iron trichloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].Cl[Fe+]Cl NQXWGWZJXJUMQB-UHFFFAOYSA-K 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 2
- SUBJHSREKVAVAR-UHFFFAOYSA-N sodium;methanol;methanolate Chemical compound [Na+].OC.[O-]C SUBJHSREKVAVAR-UHFFFAOYSA-N 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 1
- SLWXPQIUBGMMGO-UHFFFAOYSA-N C1(=CC=CC=C1)O.C1(=CC=CC=C1)O.C1=CC=CC=C1.C1(=CC=CC=C1)O Chemical group C1(=CC=CC=C1)O.C1(=CC=CC=C1)O.C1=CC=CC=C1.C1(=CC=CC=C1)O SLWXPQIUBGMMGO-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910017135 Fe—O Inorganic materials 0.000 description 1
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 101000741788 Homo sapiens Peroxisome proliferator-activated receptor alpha Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 1
- 241001480055 Quercus mongolica Species 0.000 description 1
- 241000967211 Selaginella sinensis Species 0.000 description 1
- 241000967218 Selaginella tamariscina Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000006701 autoxidation reaction Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 125000005909 ethyl alcohol group Chemical group 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010262 high-speed countercurrent chromatography Methods 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 150000004698 iron complex Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940079877 pyrogallol Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000002371 ultraviolet--visible spectrum Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (7)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710097598.4A CN106883272B (zh) | 2017-02-22 | 2017-02-22 | 双黄酮-铁配合物及其制备方法和应用 |
PCT/CN2018/076732 WO2018153328A1 (zh) | 2017-02-22 | 2018-02-13 | 双黄酮-铁配合物及其制备方法和应用 |
US16/487,848 US10889606B2 (en) | 2017-02-22 | 2018-02-13 | Biflavone-iron complex, preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710097598.4A CN106883272B (zh) | 2017-02-22 | 2017-02-22 | 双黄酮-铁配合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106883272A CN106883272A (zh) | 2017-06-23 |
CN106883272B true CN106883272B (zh) | 2019-06-18 |
Family
ID=59179617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710097598.4A Expired - Fee Related CN106883272B (zh) | 2017-02-22 | 2017-02-22 | 双黄酮-铁配合物及其制备方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10889606B2 (zh) |
CN (1) | CN106883272B (zh) |
WO (1) | WO2018153328A1 (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108409799B (zh) * | 2018-03-03 | 2020-10-13 | 广西师范大学 | 可用于光动力治疗的配合物及其制备方法 |
CN114624367B (zh) * | 2020-12-14 | 2023-05-09 | 四川大学 | 一种采用固态氧鎓盐无溶剂加压提取竹叶黄酮的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101857583A (zh) * | 2009-04-08 | 2010-10-13 | 温州医学院 | 异黄酮类金属配合物制备方法及抗肿瘤医药用途 |
CN101891783B (zh) * | 2010-06-23 | 2013-04-03 | 四川大学 | 黄酮-金属络合微球及其制备方法与应用 |
CN106883273B (zh) * | 2017-02-22 | 2019-06-18 | 南京林业大学 | 双黄酮-钴配合物及其制备方法和应用 |
CN106905371B (zh) * | 2017-02-22 | 2019-11-12 | 南京林业大学 | 双黄酮-锰配合物及其制备方法和应用 |
CN106749344B (zh) * | 2017-02-22 | 2018-12-25 | 南京林业大学 | 双黄酮-铜配合物及其制备方法和应用 |
CN106892946B (zh) * | 2017-02-22 | 2019-11-12 | 南京林业大学 | 双黄酮-镍配合物及其制备方法和应用 |
CN106905353B (zh) * | 2017-02-22 | 2018-10-09 | 南京林业大学 | 双黄酮-锌配合物及其制备方法和应用 |
-
2017
- 2017-02-22 CN CN201710097598.4A patent/CN106883272B/zh not_active Expired - Fee Related
-
2018
- 2018-02-13 US US16/487,848 patent/US10889606B2/en active Active
- 2018-02-13 WO PCT/CN2018/076732 patent/WO2018153328A1/zh active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2018153328A1 (zh) | 2018-08-30 |
US10889606B2 (en) | 2021-01-12 |
CN106883272A (zh) | 2017-06-23 |
US20200239506A1 (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106749344B (zh) | 双黄酮-铜配合物及其制备方法和应用 | |
CN106905353B (zh) | 双黄酮-锌配合物及其制备方法和应用 | |
CN106892946B (zh) | 双黄酮-镍配合物及其制备方法和应用 | |
Zhou et al. | Synthesis, characterization, antioxidative and antitumor activities of solid quercetin rare earth (III) complexes | |
Saif et al. | Synthesis, characterization, and antioxidant/cytotoxic activity of new chromone Schiff base nano-complexes of Zn (II), Cu (II), Ni (II) and Co (II) | |
Hussain et al. | Enhancing the photocytotoxic potential of curcumin on terpyridyl lanthanide (III) complex formation | |
CN106905371B (zh) | 双黄酮-锰配合物及其制备方法和应用 | |
Sirajuddin et al. | Organotin (IV) derivatives based on 2-((2-methoxyphenyl) carbamoyl) benzoic acid: Synthesis, spectroscopic characterization, assessment of antibacterial, DNA interaction, anticancer and antileishmanial potentials | |
Salassa et al. | Ligand-selective photodissociation from [Ru (bpy)(4AP) 4] 2+: a spectroscopic and computational study | |
Kostova et al. | New cerium (III) complexes of coumarins–synthesis, characterization and cytotoxicity evaluation | |
CN106883272B (zh) | 双黄酮-铁配合物及其制备方法和应用 | |
El-Medani et al. | Spectroscopic, crystal structural, theoretical and biological studies of phenylacetohydrazide Schiff base derivatives and their copper complexes | |
CN106883273B (zh) | 双黄酮-钴配合物及其制备方法和应用 | |
Kostova et al. | Antineoplastic activity of new lanthanide (cerium, lanthanum and neodymium) complex compounds | |
Kostova et al. | Theoretical, spectral characterization and antineoplastic activity of new lanthanide complexes | |
Kertmen et al. | Structural characterization and antioxidant properties of Cu (II) and Ni (II) complexes derived from dicyandiamide | |
Garza-Ortiz et al. | The synthesis, chemical and biological properties of dichlorido (azpy) gold (III) chloride (azpy= 2-(phenylazo) pyridine) and the gold-induced conversion of the azpy ligand to the chloride of the novel tricyclic pyrido [2, 1-c][1, 2, 4] benzotriazin-11-ium cation | |
Zhao et al. | Synthesis, characterization and biological activity of complexes of lanthanum (III) with 2-(1′-phenyl-2′-carboxyl-3′-aza-n-butyl)-1, 10-phenanthroline and 2-(1′-p-phenol-2′-carboxyl-3′-aza-n-butyl)-1, 10-phenanthroline | |
CN101402667B (zh) | 糖基化修饰的一氧化氮供体型齐墩果酸类化合物、其制备方法及用途 | |
US10233205B2 (en) | Magnetic resonance imaging contrast agent capable of detecting hydrogen peroxide and reducing reactive oxygen species | |
Rigamonti et al. | New curcumin-derived ligands and their affinity towards Ga 3+, Fe 3+ and Cu 2+: Spectroscopic studies on complex formation and stability in solution | |
Jadoo et al. | Synthesis, characterization and DNA binding studies of rhenium (I) and (V) compounds with Schiff bases derived from 4-aminotetrahydropyran | |
CN110256502A (zh) | 一种基于钌(ⅱ)芳烃体系的配合物、制备方法及其应用 | |
Halevas et al. | Structurally characterized copper complexes of flavonoid naringenin with enhanced radical scavenging activity | |
Ochocki et al. | Synthesis, single-crystal and solution structure analysis and in vitro cytotoxic activity of two novel complexes of ruthenium (II) with in situ formed flavanone-based ligands. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170623 Assignee: SPECTRUM DETECTION (SUZHOU) Co.,Ltd. Assignor: Nanjing Forestry University Contract record no.: X2019320000186 Denomination of invention: Biflavone-iron coordination compound and preparation method and application thereof Granted publication date: 20190618 License type: Common License Record date: 20191029 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: SPECTRUM DETECTION (SUZHOU) Co.,Ltd. Assignor: NANJING FORESTRY University Contract record no.: X2019320000186 Date of cancellation: 20201223 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20170623 Assignee: SPECTRUM DETECTION (SUZHOU) Co.,Ltd. Assignor: NANJING FORESTRY University Contract record no.: X2020320000405 Denomination of invention: Biflavone iron complex and its preparation and Application Granted publication date: 20190618 License type: Common License Record date: 20201228 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190618 |